Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc.ATNM · Entity 7435 | Chief Financial Officer | March 31, 2025 | April 02, 2025 |
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Chief Financial Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Actinium Pharmaceuticals, Inc.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.70 · Expires 2025-10-01 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-31 · Disposition to issuer · Disposed 3,333 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.70 · Expires 2026-04-14 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-31 · Disposition to issuer · Disposed 1,666 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.70 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-31 · Disposition to issuer · Disposed 3,333 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.49 · Expires 2028-07-13 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-31 · Disposition to issuer · Disposed 8,833 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.96 · Expires 2029-07-12 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-31 · Disposition to issuer · Disposed 13,333 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.55 · Expires 2030-08-12 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-31 · Disposition to issuer · Disposed 59,066 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2031-09-01 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-03-31 · Disposition to issuer · Disposed 107,463 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 · Expires 2032-07-01 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-03-31 · Disposition to issuer · Disposed 256,438 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2033-12-28 | Direct | 0 |
Reported balance
After 2025-03-31 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-03-31 · Disposition to issuer · Disposed 253,123 · Balance 0 F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration.
CNS Pharmaceuticals, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2036-03-02 | Direct | 9,500 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 9,500 · Balance 9,500 F1: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F3: Issued in connection with the reporting person's employment with the Company. F2: The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Company common stock.
F2: The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 17:01 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 9,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-001489 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2036-03-02 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 253,123 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 9 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 253,123 shares Expires 2033-12-28 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 256,438 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 8 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 256,438 shares Expires 2032-07-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 107,463 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 7 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,463 shares Expires 2031-09-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 59,066 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 6 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,066 shares Expires 2030-08-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,333 | $0.00 Strike: $6.96 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 5 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,333 shares Expires 2029-07-12 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,833 | $0.00 Strike: $23.49 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 4 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,833 shares Expires 2028-07-13 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $41.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 3 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2027-03-14 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,666 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 2 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,666 shares Expires 2026-04-14 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $53.70 | $0.00 |
DisclosureSEC source: 0001213900-25-028225 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2025-10-01 F1 · derivative.exercise_price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · price: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. F1 · derivative.exercise_date: Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 253,123 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001213900-23-100077 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,123 Underlying: Common Stock · 253,123 shares Expires 2033-12-28 F1 · derivative.exercise_price: This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 23:19 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 256,438 | $0.00 Strike: $4.96 | $0.00 |
DisclosureSEC source: 0001213900-22-036877 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,348 Underlying: Common Stock · 256,438 shares Expires 2032-07-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:02 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 107,463 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001213900-21-046684 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,463 Underlying: Common Stock · 107,463 shares Expires 2031-09-01 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:21 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantStock Option (Right to Buy) · Derivative | 59,066 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001213900-20-022342 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,066 Underlying: Common Stock · 59,066 shares Expires 2030-08-12 F1 · derivative.exercise_price: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant. F2 · derivative.exercise_date: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested. Read SEC document |
| July 12, 2019 Filed Jul 16, 2019 21:10 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 400,000 | $0.23 Strike: $0.23 | $92,800.00 |
DisclosureSEC source: 0001213900-19-012881 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-07-12 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 21:10 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 10,000 | $0.44 | $4,350.00 |
DisclosureSEC source: 0001213900-18-017143 · ownership.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 21:11 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | GrantOptions to purchase common stock · Derivative | 265,000 | $0.78 Strike: $0.78 | $207,468.50 |
DisclosureSEC source: 0001213900-18-009315 · ownership.xml · derivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2028-07-13 F1 · derivative.exercise_date: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 22:08 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon Stock | 12,000 | $0.50 | $6,000.00 |
DisclosureSEC source: 0001213900-18-007754 · f4061518oloughlin_actinium.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries B Warrants · Derivative | 7,500 | $0.50 Strike: $0.70 | $3,750.00 |
DisclosureSEC source: 0001213900-18-002726 · f4030618oloughlin_actinium.xml · derivative · entry 3 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2020-09-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherSeries A Warrants · Derivative | 2,500 | $0.50 Strike: $0.60 | $1,250.00 |
DisclosureSEC source: 0001213900-18-002726 · f4030618oloughlin_actinium.xml · derivative · entry 2 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2019-03-06 Read SEC document |
| March 06, 2018 Filed Mar 8, 2018 21:20 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | OtherCommon Stock | 10,000 | $0.50 | $5,000.00 |
DisclosureSEC source: 0001213900-18-002726 · f4030618oloughlin_actinium.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| June 15, 2017 Filed Jun 15, 2017 20:51 UTC | Actinium Pharmaceuticals, Inc. ATNM · Entity 7435 | PurchaseCommon stock | 3,500 | $1.17 | $4,095.00 |
DisclosureSEC source: 0001213900-17-006527 · f4061517oloughlin_actinium.xml · nonDerivative · entry 1 O'Loughlin Steve · CIK 0001615840 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.